ACST News and Press, Acasti Pharma Inc. From 01/03/22

LAVAL, Québec, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D’Alvise, President and CEO of Acasti, will be presenting at the H.C. Wainwright BioConnect 2022 C...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips i3 Interactive (OTCMKTS: BLITF ) stock is rising higher on Thursday despite a lack of news from the mobile gambling company. Source: Shutterstock Even without news, we’re seeing heavy trading of BLITF s...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Acasti Pharma (NASDAQ: ACST ) are jumping more than 25% higher today after a major investment firm initiated coverage. ACST stock has declined by more than 50% year to date (YTD), vastly trailing the S&...

3 Penny Stocks to Add to Your Watchlist With 2022 On The Way With such a long list of penny stocks to watch, how can investors understand which small-caps are the best? Well, there are a handful of penny stocks that traders are watching right now. If you’ve invested in either...

Gainers: BiondVax (NASDAQ:BVXV) +96%. SeaChange (NASDAQ:SEAC) +46%. Acasti (NASDAQ:ACST) +43%. Society Pass (NASDAQ:SOPA) +30%. ALJ Regional Holdings (NASDAQ:ALJJ) +26%. Red Cat (OTCQB:RCAT) +23%. Getnet Adquirencia (NASDAQ:GET) +23%. Lottery (NASDAQ:LTRY) +20%. Bellerophon Therapeutics (NASD...

BiondVax Pharmaceuticals (NASDAQ:BVXV) +55% signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany. BioRestorative Therapi...

Acasti Pharma (NASDAQ:ACST) soars 20.7% premarket after Oppenheimer launched coverage at Outperform, with price target of $6. Acasti’s merger with Grace Therapeutics gives it “a diversified, late- stage, orphan drug pipeline and bench strength,” writes Oppenheim...

Acasti Pharma (NASDAQ:ACST) said that its pivotal pharmacokinetic (PK) bridging study for GTX-104 reached all primary endpoints based on an interim look at the data from the first 20 of 50 normal healthy subjects in the trial. Being developed as an IV infusion for patients with Subarachnoid H...

LAVAL, Québec, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced positive results for GTX-104 based on its interim analysis of the first 20 of 50 normal healthy subjects in its pi...

LAVAL, Québec, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D’Alvise, President and CEO of Acasti Pharma, will be participating in the Benzinga All Access eve...